115 related articles for article (PubMed ID: 6330700)
21. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.
Railo M; Nordling S; von Boguslawsky K; Leivonen M; Kyllönen L; von Smitten K
Br J Cancer; 1993 Sep; 68(3):579-83. PubMed ID: 8394732
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical detection of carcinoembryonic antigen in infiltrating duct carcinomas of the breast: correlation with morphofunctional parameters and prognostic significance.
d'Amore ES; Gloghini A; Margallo E; Margiocco M; Nicoló G
Arch Anat Cytol Pathol; 1986; 34(2):89-94. PubMed ID: 3022656
[No Abstract] [Full Text] [Related]
23. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.
Gupta S; Joshi K; Wig JD; Arora SK
Acta Oncol; 2007; 46(6):792-7. PubMed ID: 17653902
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of carcinoembryonic antigen level of serum and tumor tissue in breast cancer patients (author's transl)].
Kitamura M; Tominaga T; Kaneko H; Hayashi K; Takahashi I; Saito T; Ito I
Nihon Gan Chiryo Gakkai Shi; 1981 Feb; 16(1):35-43. PubMed ID: 6267147
[No Abstract] [Full Text] [Related]
26. Gains and losses of HLA class II (DR) and CD4 in atypical hyperplasia, carcinoma in situ and infiltrating ductal carcinoma of the breast.
Tamiolakisl D; Venizelos I; Lambropoulou M; Jivannakis T; Seliniotakis E; Tsikouras P; Limberis V; Tsalkidis A; Papadopoulos N
Acta Medica (Hradec Kralove); 2004; 47(4):257-62. PubMed ID: 15844251
[TBL] [Abstract][Full Text] [Related]
27. Search for disease-related cytotoxicity in mammary tumor patients.
Bakacs T; Klein E; Ljungström KG
Cancer Lett; 1978 Apr; 4(4):191-7. PubMed ID: 206348
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic significance of tumor grading in breast cancer].
Reiner A; Holzner JH; Reiner G; Spona J; Schemper M; Kolb R; Jakesz R
Verh Dtsch Ges Pathol; 1985; 69():365-9. PubMed ID: 3006387
[No Abstract] [Full Text] [Related]
29. Studies of a breast cancer antigen in patients.
Estes NC; Morse PA; Humphrey LJ; Volenec PJ
Surg Forum; 1975; 26():116-7. PubMed ID: 175511
[No Abstract] [Full Text] [Related]
30. [Immunohistochemical study on HLA expression of human breast cancer].
Nakazawa T; Yamamoto K; Kohno N; Saitoh Y
Nihon Geka Gakkai Zasshi; 1990 Apr; 91(4):508-14. PubMed ID: 2165559
[TBL] [Abstract][Full Text] [Related]
31. Immunological status in breast cancer patients undergoing radiotherapy.
Chander S; Chandra M
Indian J Med Sci; 1987 Dec; 41(12):269-74. PubMed ID: 2835315
[No Abstract] [Full Text] [Related]
32. Unaltered immunocompetence in patients with non-disseminated breast cancer at the time of diagnosis.
Ludwig CU; Hartmann D; Landmann R; Wesp M; Rosenfelder G; Stucki D; Buser M; Obrecht JP
Cancer; 1985 Apr; 55(8):1673-8. PubMed ID: 3872158
[TBL] [Abstract][Full Text] [Related]
33. Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumor immunity.
Hellström I; Hellström KE; Sjögren HO; Warner GA
Int J Cancer; 1971 Sep; 8(2):185-91. PubMed ID: 4332366
[No Abstract] [Full Text] [Related]
34. Routine histoprognostic factors in early-stage breast carcinoma: a review.
Gilchrist KW
Cancer Invest; 1992; 10(6):565-73. PubMed ID: 1330222
[No Abstract] [Full Text] [Related]
35. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas.
Iwamoto M; Shinohara H; Miyamoto A; Okuzawa M; Mabuchi H; Nohara T; Gon G; Toyoda M; Tanigawa N
Int J Cancer; 2003 Mar; 104(1):92-7. PubMed ID: 12532424
[TBL] [Abstract][Full Text] [Related]
36. Carcinoma of breast presenting as gastric cancer: diagnosis by immunoperoxidase staining patterns.
Finch PJ; Rogers K; Holt S
J R Coll Surg Edinb; 1989 Aug; 34(4):225-6. PubMed ID: 2553937
[No Abstract] [Full Text] [Related]
37. T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients.
Alam SM; Clark JS; Leech V; Whitford P; George WD; Campbell AM
Immunol Lett; 1992 Feb; 31(3):279-83. PubMed ID: 1347754
[TBL] [Abstract][Full Text] [Related]
38. Lymphoreticular malignancies and immunologic abnormalities in a sibship.
Potolsky AI; Heath CW; Buckley CE; Rowlands DT
Am J Med; 1971 Jan; 50(1):42-8. PubMed ID: 4321840
[No Abstract] [Full Text] [Related]
39. Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.
Fracol M; Datta J; Lowenfeld L; Xu S; Zhang PJ; Fisher CS; Czerniecki BJ
Ann Surg Oncol; 2017 Feb; 24(2):407-417. PubMed ID: 27663569
[TBL] [Abstract][Full Text] [Related]
40. Relationships between histology, monoclonal antibody reactivity, and prognosis in breast cancer.
Yuan D; Dawson PJ
Hum Pathol; 1987 Nov; 18(11):1097-100. PubMed ID: 2824320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
